Determinants of lipid goal achievement in patients on extended-release nicotinic acid/laropiprant in primary care clinical practice

References

• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004;364:937-52
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
   PubMed Web of Science ®Google Scholar
• Driscoll A, Beauchamp A, Lyubomirsky G, et al. Suboptimal management of cardiovascular risk factors in coronary heart disease patients in primary care occurs particularly in females. Intern Med J 2011;41:730-6
   PubMed Web of Science ®Google Scholar
• Tomasik T, Jozwiak J, Windak A, et al. Prevention of coronary heart disease in primary medical care in Poland: results from the LIPIDOGRAM study. Eur J Cardiovasc Prev Rehabil 2011;18:287-96
   PubMed Web of Science ®Google Scholar
• Nieburg I, Kahan T. Cardiovascular risk factors are not treated to target in hypertensive patients in primary care. Blood Press 2010;19:176-81
   PubMed Web of Science ®Google Scholar
• McCrate F, Godwin M, Murphy L. Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: a study of primary care practices in St John's, Nfld. Can Fam Physician 2010;56:e13-9
   PubMed Web of Science ®Google Scholar
• Perry CM. Extended-release niacin (nicotinic acid)/laropiprant. Drugs 2009;69:1665-79
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Kei A, et al. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr Vasc Pharmacol 2011;9:385-400
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70
   PubMed Web of Science ®Google Scholar
• Gleim G, Ballantyne C, Liu N, et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009;16:90-7
   Google Scholar
• Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
   PubMed Web of Science ®Google Scholar
• Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-30
   PubMed Web of Science ®Google Scholar
• Kush D, Hu DY, Ye P, et al. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Cardiology 2009;114:192-8
   PubMed Web of Science ®Google Scholar
• Knight EL, Bohn RL, Wang PS, et al. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension 2001;38:809-14
   PubMed Web of Science ®Google Scholar
• Steinhagen-Thiessen E, Dänschel W, Buffleben C, et al. Extended-release nicotinic acid/laropiprant for lipid management: observational study in clinical practice. Int J Clin Pract 2012 (in press)
   Google Scholar
• European Epidemiology Federation. Good Epidemiological Practice (GEP): Proper Conduct in Epidemiologic Research. Updated 2007. Available at: http://www.ieaweb.org/index.php?view=article&catid=20%3Agood-epidemiological-practice-gep&id=15%3Agood-epidemiological-practice-gep&format=pdf&option=com_content&Itemid=43 [Last accessed 23 November 2012]
   Google Scholar
• Faxon DP, Schwamm LH, Pasternak RC, et al. Improving quality of care through disease management: principles and recommendations from the American Heart Association's Expert Panel on Disease Management. Circulation 2004;109:2651-4
   PubMed Web of Science ®Google Scholar
• Busse R. Disease management programs in Germany's statutory health insurance system. Health Aff (Millwood) 2004;23:56-67
   PubMed Web of Science ®Google Scholar
• Beyer M, Gensichen J, Szecsenyi J, et al. [Effectiveness of German disease management programs – problems of clinical evaluation research in the light of a study protocol]. Z Arztl Fortbild Qualitatssich 2006;100:355-63
   PubMedGoogle Scholar
• Bundesversicherungsamt (BVS). Kriterien des Bundesversicherungsamtes zur Evaluation strukturierter Behandlungsprogramme [Criteria of the BVS on the evaluation of disease management programs]. Version 5.3., Bonn, Germany, 30 September 2011. Available at: http://www.bundesversicherungsamt.de [Last accessed on 23 November 2012]
   Google Scholar
• Miksch A, Laux G, Ose D, et al. Is there a survival benefit within a German primary care-based disease management program? Am J Manag Care 2010;16:49-54
   PubMed Web of Science ®Google Scholar
• Bestehorn K, Jannowitz C, Karmann B, et al. Characteristics, management and attainment of lipid target levels in patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. BMC Public Health 2009;9:280
   PubMed Web of Science ®Google Scholar
• Berthold HK, Bestehorn KP, Jannowitz C, et al. Disease management programs in type 2 diabetes: quality of care. Am J Manag Care 2011;17:393-403
   PubMed Web of Science ®Google Scholar
• Linder R, Ahrens S, Koppel D, et al. The benefit and efficiency of the disease management program for type 2 diabetes. Dtsch Arztebl Int 2011;108:155-62
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67
   PubMed Web of Science ®Google Scholar
• Mosca L, Merz NB, Blumenthal RS, et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 2005;111:488-93
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96:556-63
   PubMed Web of Science ®Google Scholar
• Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119:676-83
   PubMed Web of Science ®Google Scholar
• Hildemann S, Karmann B, Pittrow D, et al. Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care. Curr Med Res Opin 2008;24:1659-68
   PubMed Web of Science ®Google Scholar
• Bermingham M, Hayden J, Dawkins I, et al. Prospective analysis of LDL-C goal achievement and self-reported medication adherence among statin users in primary care. Clin Ther 2011;33:1180-9
   PubMed Web of Science ®Google Scholar
• Laupacis A, Mamdani M. Observational studies of treatment effectiveness: some cautions. Ann Intern Med 2004;140:923-24
   PubMed Web of Science ®Google Scholar